JP5792185B2 - 線維増殖性障害および癌からなる群から選択されるβ−カテニン媒介障害を治療するための医薬組成物 - Google Patents

線維増殖性障害および癌からなる群から選択されるβ−カテニン媒介障害を治療するための医薬組成物 Download PDF

Info

Publication number
JP5792185B2
JP5792185B2 JP2012543426A JP2012543426A JP5792185B2 JP 5792185 B2 JP5792185 B2 JP 5792185B2 JP 2012543426 A JP2012543426 A JP 2012543426A JP 2012543426 A JP2012543426 A JP 2012543426A JP 5792185 B2 JP5792185 B2 JP 5792185B2
Authority
JP
Japan
Prior art keywords
nefopam
pharmaceutical composition
cancer
catenin
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012543426A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013513625A (ja
JP2013513625A5 (enExample
Inventor
アルマン，ベンジャミン・エイ
プーン，レイモンド
ホン，ヘレン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hospital for Sick Children
Original Assignee
Hospital for Sick Children
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44166687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5792185(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hospital for Sick Children filed Critical Hospital for Sick Children
Publication of JP2013513625A publication Critical patent/JP2013513625A/ja
Publication of JP2013513625A5 publication Critical patent/JP2013513625A5/ja
Application granted granted Critical
Publication of JP5792185B2 publication Critical patent/JP5792185B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
JP2012543426A 2009-12-15 2010-12-15 線維増殖性障害および癌からなる群から選択されるβ−カテニン媒介障害を治療するための医薬組成物 Expired - Fee Related JP5792185B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28663309P 2009-12-15 2009-12-15
US61/286,633 2009-12-15
PCT/CA2010/002014 WO2011072394A1 (en) 2009-12-15 2010-12-15 METHOD OF TREATING SCARS AND ß-CATENIN-MEDIATED DISORDERS USING NEFOPAM COMPOUNDS

Publications (3)

Publication Number Publication Date
JP2013513625A JP2013513625A (ja) 2013-04-22
JP2013513625A5 JP2013513625A5 (enExample) 2014-02-06
JP5792185B2 true JP5792185B2 (ja) 2015-10-07

Family

ID=44166687

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012543426A Expired - Fee Related JP5792185B2 (ja) 2009-12-15 2010-12-15 線維増殖性障害および癌からなる群から選択されるβ−カテニン媒介障害を治療するための医薬組成物

Country Status (10)

Country Link
US (4) US8957107B2 (enExample)
EP (1) EP2512468B1 (enExample)
JP (1) JP5792185B2 (enExample)
KR (1) KR101753439B1 (enExample)
CN (2) CN102781442B (enExample)
BR (1) BR112012014471A2 (enExample)
CA (1) CA2782472C (enExample)
DK (1) DK2512468T3 (enExample)
ES (1) ES2594900T3 (enExample)
WO (1) WO2011072394A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102781442B (zh) * 2009-12-15 2016-02-17 儿童医院 使用奈福泮化合物治疗瘢痕和β-联蛋白介导的疾病的方法
US10736905B1 (en) 2016-09-09 2020-08-11 Shahin Fatholahi Nefopam dosage forms and methods of treatment
EP4656191A1 (en) * 2017-06-02 2025-12-03 Iterion Therapeutics, Inc. Methods for treatment of fibrotic diseases
US10736874B1 (en) 2017-09-08 2020-08-11 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US11446311B2 (en) 2017-09-08 2022-09-20 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US11266637B2 (en) * 2018-06-01 2022-03-08 Iterion Therapeutics, Inc. Formulations of tegavivint and related compounds
CN110638780A (zh) * 2019-09-11 2020-01-03 华益药业科技(安徽)有限公司 一种盐酸奈福泮片及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US6630142B2 (en) 1999-05-03 2003-10-07 Zymogenetics, Inc. Method of treating fibroproliferative disorders
US6638981B2 (en) * 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
US20030190308A1 (en) * 2002-03-19 2003-10-09 Braun Ralph P. Adjuvant
GB0213869D0 (en) * 2002-06-17 2002-07-31 Arakis Ltd The treatment of pain
PT1572672E (pt) 2002-12-20 2008-10-02 Sosei R & D Ltd Benzoxazocinas e sua utilização como inibidores de reabsorção de monoamina
US20060019940A1 (en) 2002-12-20 2006-01-26 Baxter Andrew D Novel benzoxazocines and their therapeutic use
GB0330049D0 (en) 2003-12-24 2004-02-04 Arakis Ltd The treatment of neuropathic pain conditions
WO2005103019A1 (en) 2004-04-21 2005-11-03 Sosei R&D Ltd. Benzoxazocines and their therapeutic use as monoamine reuptake inhibitors
GB2413322A (en) 2004-04-21 2005-10-26 Arakis Ltd Nefopam analogues
CN1569004A (zh) * 2004-05-13 2005-01-26 南昌弘益科技有限公司 盐酸奈福泮滴丸及其制备方法
FR2880275B1 (fr) 2005-01-06 2007-04-13 Biocodex Utilisation de composes pharmacologiques pour la prevention ou le traitement de la tolerance aigue aux morphiniques
GB0506835D0 (en) 2005-04-04 2005-05-11 Arakis Ltd Therapeutic use of nefopam
GB0515703D0 (en) 2005-07-29 2005-09-07 Arakis Ltd Therapeutic use of nefopam
CN101002756A (zh) 2007-01-19 2007-07-25 陶燃 盐酸奈福泮的透皮贴片制剂
GB0721013D0 (en) 2007-10-25 2007-12-05 Sosei R & D Ltd New Salts
MX2010013931A (es) 2008-06-16 2011-06-01 Academia Sinica Diagnosis de cancer basada en niveles de anticuerpos contra globo h y sus fragmentos.
GB2461874B (en) 2008-07-14 2012-11-21 Caltec Ltd Separation system and method
FR2940911B1 (fr) * 2009-01-13 2012-09-21 Philippe Perovitch Formulation pour l'administration par voie trans-muqueuse buccale de molecules antalgiques et/ou anti-spasmodiques
CN102781442B (zh) * 2009-12-15 2016-02-17 儿童医院 使用奈福泮化合物治疗瘢痕和β-联蛋白介导的疾病的方法

Also Published As

Publication number Publication date
WO2011072394A1 (en) 2011-06-23
EP2512468B1 (en) 2016-08-24
US8957107B2 (en) 2015-02-17
HK1174565A1 (zh) 2013-06-14
CN105687185A (zh) 2016-06-22
US20150105363A1 (en) 2015-04-16
US9566263B2 (en) 2017-02-14
CN102781442A (zh) 2012-11-14
HK1224224A1 (zh) 2017-08-18
DK2512468T3 (en) 2016-11-14
CN105687185B (zh) 2019-07-09
CA2782472A1 (en) 2011-06-23
KR101753439B1 (ko) 2017-07-19
CA2782472C (en) 2019-04-16
US20170172980A1 (en) 2017-06-22
ES2594900T3 (es) 2016-12-23
US10722493B2 (en) 2020-07-28
KR20120110117A (ko) 2012-10-09
BR112012014471A2 (pt) 2017-06-06
US20170281594A1 (en) 2017-10-05
EP2512468A4 (en) 2013-08-07
JP2013513625A (ja) 2013-04-22
CN102781442B (zh) 2016-02-17
EP2512468A1 (en) 2012-10-24
US20120294928A1 (en) 2012-11-22

Similar Documents

Publication Publication Date Title
Chen et al. Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3β-regulated suppression of β-catenin signaling
KR102077871B1 (ko) 체세포 줄기 세포의 비대칭 분열을 향상시키기 위한 ｃｂｐ/카테닌 길항제
US10722493B2 (en) Methods for treating fibroproliferative disorders in a mammal
KR101928543B1 (ko) 니클로사마이드를 함유하는 Axin-GSK3 단백질 결합 관련 질환 치료용 약학조성물
JP7197370B2 (ja) がんの予防および／または治療のための化合物、組成物および方法
PT2151438E (pt) Produto farmacêutico contendo agonista de ppar
US20160213669A1 (en) Use of n-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in combination with histone deacetylase inhibitors for treatment of cancer
EP3579840B1 (en) Treatment of cancer and inhibition of metastasis
JP2015534942A (ja) Ｃｂｐ／カテニン阻害剤を用いる過剰増殖性及び前がん性皮膚病の治療
WO2013149026A2 (en) Use of n-(4-((3-(2-amino-4-pyrimidinyl) -2-pyridinyl)oxy)phenyl)-4-(4-methyl -2-thienyl)-1-phthalazinamine in combination with histone deacetylase inhibitors for treatment of cancer
CN115813892B (zh) 原儿茶醛与达卡巴嗪的药物联合及其在治疗恶性黑色素瘤中的用途
HK1224224B (en) Method of treating aggressive fibromatoses and betacatenin-mediated disorders using nefopam compounds
HK1174565B (en) Method of treating scars and ss-catenin-mediated disorders using nefopam compounds
EP4501324A1 (en) Wound treatment composition
Domingues Possible therapies to overcome resistance to mapk inhibitors in mutant braf melanoma
WO2011051938A1 (en) Composition for treatment of thyroid cancer with fts and analogs thereof
CN112656797A (zh) chaetocin在制备抑制动脉粥硬化药物中的应用
WO2018128517A1 (ko) 니클로사미드를 함유하는 Ras 암유전자 표적치료 관련 암의 치료 또는 예방용 약학 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131211

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150609

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150701

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150723

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150805

R150 Certificate of patent or registration of utility model

Ref document number: 5792185

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees